August 19, 2026 | Supplement Industry Insights
FDA has proposed one of the most significant changes to the GRAS notification process in decades. Here’s what supplement brands, formulators, and product development teams need to know — and what they can do now to prepare.
On August 11, 2026, the U.S. Food and Drug Administration (FDA) published a proposed rule that would fundamentally change how companies use the Generally Recognized as Safe, or GRAS, pathway for substances added to human and animal food.
Under the current system, a company that independently concludes that a substance is GRAS under its intended conditions of use may voluntarily submit a GRAS notice to FDA. However, submission is not currently required. As a result, FDA may not know about every substance being marketed based on an independent GRAS conclusion.
The proposed rule would change that framework. If finalized as proposed, companies introducing covered substances into interstate commerce under the GRAS provision would generally need to notify FDA and provide the basis for their GRAS conclusion, unless an exception applies.
FDA says mandatory notification would give the agency greater visibility into substances entering the food supply and help it determine whether their uses qualify as GRAS or instead require food additive review and approval. [1]
Remember, the proposed rule is not currently law, and the existing GRAS notification framework remains in effect. FDA is accepting comments on the proposal through December 9, 2026, under Docket No. FDA-2025-N-3262. [1]
For supplement brands, the implications require some nuance. Dietary ingredients used in dietary supplements have a distinct statutory framework under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Therefore, brands should not assume that every dietary ingredient in a supplement will suddenly require a GRAS notice.
Nevertheless, the proposal deserves close attention from supplement companies. Regulatory status depends on the substance, its intended use, and the applicable statutory pathway. In addition, supplement companies increasingly develop products and ingredient systems that cross conventional food, functional food, powder, and other adjacent categories.
For brand owners and formulators, the larger lesson is clear: ingredient regulatory status, supporting safety documentation, intended conditions of use, and supplier qualification may need to become even more integrated into early product development.
FDA is proposing to replace the current voluntary GRAS notification system with a mandatory notification framework for covered GRAS uses. Although the rule is not final, now is an appropriate time for brands to understand how their ingredients are supported and where potential documentation gaps may exist.
For supplement brands, the immediate priority is not to panic or reformulate products unnecessarily. Instead, brands should understand the regulatory basis for the ingredients they use, identify where independent GRAS conclusions are being relied upon, and determine whether their documentation will support future regulatory scrutiny.
GRAS stands for Generally Recognized as Safe. Under sections 201(s) and 409 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), substances intentionally added to food generally require FDA premarket approval as food additives. However, an intended use may fall outside that requirement when qualified experts generally recognize the substance as safe under its intended conditions of use, or another statutory exclusion applies. [1,2]
Importantly, GRAS is not simply a designation attached permanently to an ingredient. Instead, a GRAS conclusion relates to a substance under specific conditions of intended use. Those conditions can include the foods in which the substance will be used, its use level, manufacturing method, specifications, and expected dietary exposure. FDA evaluates these factors when reviewing a GRAS notice. [2,3]
Under the current regulatory framework, a company can determine that a substance is GRAS under its intended conditions of use without submitting that conclusion to FDA. Companies may voluntarily submit a GRAS notice, and FDA strongly encourages them to use the notification program. However, notification itself is not currently mandatory. [2,3]
When a company voluntarily submits a GRAS notice, FDA evaluates whether the notice provides a sufficient basis for the company’s GRAS conclusion. FDA generally responds by stating that it has no questions regarding the notifier’s conclusion, that the notice does not provide a sufficient basis for a GRAS conclusion, or that FDA has ceased evaluating the notice at the notifier’s request. [3]
FDA also maintains a public inventory of submitted GRAS notices and its response letters. [4]
However, independently reached GRAS conclusions that are never submitted to FDA do not enter that notification system. Consequently, FDA does not have complete visibility into every substance or use entering the food supply based on a GRAS conclusion.
FDA’s proposed rule is intended to close that information gap.
According to FDA, an unknown number of substances are currently introduced into the market under the GRAS provision without FDA receiving information about the basis for those conclusions. The agency believes mandatory notification would provide greater transparency and help regulators identify substances that may require additional safety evaluation or food additive approval. [1]
In addition, FDA says mandatory notification would help the agency determine whether GRAS conclusions have an adequate scientific basis and whether appropriate supporting documentation exists. [1,5]
For the food and supplement industries, this represents an important shift in regulatory oversight. The GRAS standard itself would remain centered on safety and general recognition among qualified experts. However, for uses subject to the proposed notification requirement, companies would no longer have the same ability to rely on an independent GRAS conclusion without notifying FDA.
Key Takeaway: The proposed rule does not eliminate the GRAS pathway. Instead, FDA is proposing greater visibility and oversight by making notification mandatory for covered GRAS uses that currently may enter commerce without FDA notification.
The most significant change is straightforward: GRAS notification would move from a voluntary process to a mandatory requirement for covered uses of substances introduced into interstate commerce under the GRAS provision. [1,5]
However, the proposal involves more than simply requiring an additional filing. It could change how companies document ingredient safety, qualify suppliers, evaluate intended uses, plan product-development timelines, and maintain regulatory records.
| Regulatory Issue | Current Framework | Proposed Framework |
|---|---|---|
| GRAS notification to FDA | A company may voluntarily notify FDA after reaching a GRAS conclusion. | Notification generally would become mandatory for covered uses relying on the GRAS provision. |
| Independent GRAS conclusions | A company may reach an independent GRAS conclusion without submitting it to FDA. | Covered uses generally could no longer rely solely on an unnotified independent GRAS conclusion after the rule takes effect. |
| Existing independently concluded GRAS uses | No FDA notification is required solely because a company independently concludes the use is GRAS. | FDA proposes a time-limited streamlined submission pathway for qualifying uses already in interstate commerce before the final rule’s effective date. |
| New GRAS uses | Companies may choose whether to submit a GRAS notice. | Covered new uses introduced after the final rule’s effective date generally would require a GRAS notice. |
| FDA visibility | FDA does not necessarily receive information about independently concluded, unnotified GRAS uses. | FDA would receive substantially more information about substances and uses relying on the GRAS provision. |
| Public transparency | FDA’s public GRAS inventory contains submitted notices and FDA response letters, but not every independent GRAS conclusion. | Mandatory notification would expand the information available to FDA and potentially increase public visibility into GRAS uses. |
| Company procedures | Companies may maintain their own processes for independent GRAS conclusions and voluntary notification. | Companies relying on covered GRAS uses may need to revise regulatory procedures and SOPs to incorporate mandatory submissions. |
This comparison summarizes FDA’s August 2026 proposed rule. Requirements could change before a final rule is issued. [1,5]
One of the proposal’s most important provisions concerns substances already in commerce.
FDA proposes a time-limited streamlined submission option for qualifying uses of substances introduced into interstate commerce under the GRAS provision before the effective date of a final rule. Rather than requiring the complete GRAS notice contemplated for new covered uses, companies could provide specified information about existing uses during this transitional period. [1]
The proposed streamlined submission would include information such as the identity of the substance, its intended conditions of use and use levels, and information demonstrating that the substance was already introduced into interstate commerce under the GRAS provision before the final rule’s effective date. [1]
Under the proposal, this streamlined pathway would remain available for one year following the effective date of a final rule. Therefore, companies relying on existing independent GRAS conclusions could face a meaningful documentation project if the rule becomes final.
However, inclusion through this streamlined process should not be confused with FDA affirmatively determining that a substance is GRAS. FDA could subsequently determine that additional regulatory review is warranted. [1]
For covered uses introduced after the final rule’s effective date, companies generally would need to submit a GRAS notice rather than rely solely on an independent conclusion.
That change could have practical consequences for product development.
Under the proposal, FDA generally would respond to a GRAS notice within 180 days, but the agency could extend that period by up to 90 days on two separate occasions when additional time is needed. As a result, the potential agency review period could reach approximately 360 days in some circumstances. [1]
That does not mean every new supplement formulation would face a year-long FDA review. The GRAS framework does not apply uniformly to every dietary ingredient or every dietary supplement use. However, when a product or ingredient use does rely on GRAS status, regulatory strategy may need to enter the development process much earlier.
For formulators, regulatory teams, and brand owners, that creates an important operational question:
Does the regulatory support for an ingredient actually cover the substance, specifications, manufacturing process, use level, product category, and intended conditions of use being considered?
That question may become increasingly important during ingredient sourcing and formulation development.
FDA’s own economic analysis anticipates that affected companies may need to read and assess the final requirements, revise GRAS-related standard operating procedures, prepare streamlined submissions for qualifying existing uses, and prepare notices for covered new uses. [5]
Therefore, brands should view the proposal as more than a regulatory filing issue. If finalized, mandatory notification could influence how regulatory, R&D, quality, procurement, and commercialization teams work together.
Mandatory GRAS notification could move regulatory-status review further upstream in product development. Brands that understand the regulatory basis, intended conditions of use, and supporting documentation for their ingredients will be better positioned to adapt if FDA finalizes the rule.
For supplement brands, one of the most important questions is also one of the most nuanced: Does FDA’s proposed mandatory GRAS notification requirement apply to dietary supplements?
The answer is not a simple yes or no. Instead, brands need to distinguish between a dietary ingredient used in a dietary supplement and a substance or use that relies on GRAS status under the food additive provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
FDA’s proposed rule specifically addresses this distinction.
Under section 201(s) of the FD&C Act, certain categories are excluded from the definition of a “food additive.” One exclusion covers an ingredient described in section 201(ff) of the FD&C Act when that ingredient is in, or intended for use in, a dietary supplement.
Because those dietary ingredients are excluded from the statutory definition of a food additive, FDA explains that they are not eligible for classification as GRAS under the GRAS provision contained within that food additive definition. [1]
Therefore, the proposed mandatory GRAS notification rule should not be interpreted as a requirement for every dietary ingredient used in every dietary supplement to obtain GRAS status or submit a GRAS notice.
That distinction matters. Dietary ingredients may instead be subject to other dietary supplement requirements, including the New Dietary Ingredient (NDI) provisions when applicable. In fact, FDA specifically distinguishes GRAS notices from other premarket submissions, including new dietary ingredient notifications, within the proposed rule. [1]
However, the regulatory analysis should not stop at an ingredient’s name.
The same substance can potentially appear in different product categories and for different intended uses. For example, a company may evaluate an ingredient for use in a dietary supplement while another company evaluates the substance for use in a conventional food.
Those uses can involve different regulatory pathways.
For supplement brands expanding into functional foods or other adjacent categories, this distinction becomes especially important. A regulatory position supporting an ingredient in one application should not automatically be assumed to support every other application.
Therefore, regulatory teams and formulators should ask a more precise question:
What is the regulatory basis for this specific substance under our specific conditions of intended use?
That approach helps brands avoid treating “GRAS,” “dietary ingredient,” and “NDI” as interchangeable regulatory designations. They are not.
Even though dietary ingredients in dietary supplements receive separate statutory treatment, the GRAS proposal remains highly relevant to the supplement industry.
Ingredient suppliers may market substances across dietary supplement and conventional food categories. Likewise, supplement brands may develop powders, gummies, or other products whose classification and intended use require careful regulatory evaluation.
Additionally, formulations contain more than headline active ingredients. Companies should understand the regulatory basis for substances used throughout a formulation rather than relying on a generalized statement that an ingredient is “GRAS.”
The proposed rule reinforces a broader regulatory principle: regulatory status depends on the substance and its intended conditions of use.
During ingredient qualification and formulation development, supplement brands should document:
This last point deserves particular attention. FDA states in the proposal that an existing “no questions” letter may not cover a use when the identity, manufacturing process, food categories, use levels, technical effect, specifications, or other conditions differ significantly from those addressed in the original GRAS notice. [1]
In other words, seeing a GRAS Notice number on a supplier document is useful, but it should not necessarily end the regulatory review.
The proposed rule does not mean every dietary ingredient in a dietary supplement will need a GRAS notice. However, supplement brands should clearly identify the regulatory basis supporting each substance and intended use rather than treating GRAS status as a universal ingredient designation.
One of the biggest questions raised by mandatory notification involves substances already being marketed based on an independent GRAS conclusion, sometimes called “self-GRAS.”
FDA recognizes that companies have relied on the existing regulatory framework for decades. Therefore, the agency is not proposing that every existing independently concluded GRAS use automatically enter the same process proposed for a new use.
Instead, FDA proposes a temporary streamlined submission pathway for certain existing uses. [1]
Under the proposal, certain substances introduced into interstate commerce under the GRAS provision before the effective date of a final rule could qualify for an exception to the full GRAS notification requirement.
To use this exception, a company would submit specified information to FDA through a streamlined process. FDA would then place qualifying submission information on a publicly available list. [1]
The proposed submission would include information such as:
FDA would also allow the submitter to identify whether the GRAS conclusion rests on scientific procedures or experience based on common use in food, although the proposal would not require that information as part of the streamlined submission. [1]
Timing could become particularly important for companies with existing independent GRAS conclusions.
FDA proposes allowing streamlined submissions for only one year after the effective date of a final rule. After that one-year period, FDA would no longer accept submissions through this particular pathway. [1]
The proposed timeline has another important component. FDA currently proposes that a final rule would become effective 60 days after publication. The mandatory-notification provisions in proposed §§ 170.205 and 570.205 would then have a compliance date 18 months after the final rule’s effective date. [1]
That proposed sequencing would give industry time to evaluate existing uses, submit eligible substances through the streamlined process, and prepare for the mandatory notification framework.
However, none of these dates are final. FDA could revise the timelines after reviewing public comments.
This is an especially important distinction for brands and ingredient suppliers.
FDA states that placing information from a streamlined submission on its public list would not mean FDA has reviewed or determined the GRAS status of the substance under its intended conditions of use. [1]
Instead, the streamlined process would give FDA greater visibility into substances already being marketed under independent GRAS conclusions.
FDA could ask the submitter additional questions. Moreover, the agency could subsequently determine that the intended use requires submission of a complete GRAS notice or, in some circumstances, a food additive petition. [1]
Therefore, companies should avoid treating future inclusion on this list as equivalent to an FDA “no questions” letter or an FDA determination of GRAS status.
The proposal also creates an important distinction for GRAS uses FDA has already evaluated.
If an existing FDA “no questions” letter covers the same substance under the same conditions of intended use, FDA proposes an exception from the new mandatory GRAS notice requirement. [1]
However, the details matter.
FDA specifically cautions that a previous GRAS conclusion may not extend to materially different conditions. Changes in manufacturing process, specifications, food categories, use levels, technical effect, or ingredient identity could affect whether an existing notice covers the intended use. [1]
For brands, this means supplier due diligence should go beyond asking:
“Does this ingredient have a GRAS Notice number?”
A stronger question is:
“Does the GRAS notice and FDA response cover the ingredient we are purchasing, with its current specifications and manufacturing process, at our intended use level and under our intended conditions of use?”
That is a much more meaningful regulatory question.
Although the rule remains a proposal, brands and suppliers do not need to wait to organize their records.
FDA estimates approximately 2,418 streamlined human-food submissions for certain substances already introduced into interstate commerce under independent GRAS conclusions or the other assumptions described in its burden analysis. The agency estimates approximately 32 hours of preparation per streamlined submission, producing an estimated 77,376-hour one-time burden for that portion of the program. [1]
Those estimates illustrate why companies with large ingredient portfolios should not view the proposed transition simply as administrative paperwork.
Brands can begin by identifying ingredients or uses that rely on independent GRAS conclusions and determining:
This exercise can strengthen supplier qualification and regulatory readiness regardless of how FDA ultimately modifies the proposed rule.
Existing independently concluded GRAS uses would not necessarily have to start from zero under FDA’s proposal. However, the proposed streamlined pathway would be temporary, and inclusion on FDA’s public list would not constitute an FDA determination that a use is GRAS. Brands should begin identifying where they rely on independent GRAS conclusions and whether the supporting documentation actually covers their intended use.
If FDA finalizes mandatory GRAS notification, the effects could extend well beyond regulatory departments. Ingredient sourcing, supplier qualification, formulation decisions, commercialization timelines, and change control may all require greater regulatory coordination.
For supplement brands, however, the first step remains determining whether a particular substance and intended use actually rely on GRAS status. As discussed above, dietary ingredients used in dietary supplements operate under a different statutory framework. Brands should avoid applying the proposed GRAS requirements indiscriminately to every supplement ingredient.
Where GRAS status does support an intended use, the proposal could make regulatory readiness an earlier part of product development.
Ingredient selection typically starts with efficacy, formulation compatibility, sensory performance, cost, and consumer appeal. Regulatory support should receive similar consideration early in development.
For a substance relying on GRAS status, formulators should understand whether existing documentation covers the ingredient they intend to use. FDA notes that differences in identity, manufacturing process, specifications, food categories, use levels, technical effect, or other conditions can affect whether an existing GRAS conclusion applies. [1]
Therefore, two ingredients with the same common name may not necessarily present identical regulatory considerations.
For novel or highly differentiated ingredients, brands should consider regulatory status before investing heavily in formulation development, packaging, marketing, or launch planning. Resolving a regulatory gap late in commercialization can create unnecessary delays and reformulation risk.
The proposed framework also raises an important supply-chain question: Who is responsible for maintaining the regulatory support for an ingredient?
FDA’s proposal generally places the notification obligation on a person introducing a substance into interstate commerce under the GRAS provision. However, the proposal does not necessarily require every downstream manufacturer using the same substance under the same covered conditions to file a separate notice. [1]
For example, a downstream company may be able to rely on an applicable FDA “no questions” letter or qualifying streamlined submission when it covers the same substance and conditions of use. [1]
That makes supplier documentation increasingly important.
Brands should consider asking suppliers for the applicable GRAS Notice number, FDA response letter, conditions of intended use, specifications, manufacturing information relevant to regulatory status, and confirmation of whether the supplied material aligns with the substance covered by the cited regulatory documentation.
Additionally, supply agreements and qualification procedures may eventually need to address responsibility for regulatory support and notification of material changes.
Formula optimization often requires change. A brand may increase an ingredient’s use level, switch suppliers, modify specifications, use a different ingredient form, or move a successful concept into another product category.
Under a more transparent GRAS framework, those changes deserve regulatory review alongside technical review.
A higher use level, for example, could alter estimated dietary exposure. Likewise, a significant manufacturing-process change could affect the identity, composition, purity, or safety profile of a substance.
Consequently, formulators should avoid assuming that an existing GRAS conclusion automatically follows an ingredient into every formulation.
A practical change-control process should ask whether a modification affects:
This approach can help regulatory and R&D teams identify potential issues before a formulation reaches commercialization.
The proposed rule also changes how brands should think about timing.
Importantly, FDA is proposing a notification requirement rather than a conventional premarket approval system. Under the proposal, the notification requirement would be satisfied when FDA files a complete GRAS notice. A company would not necessarily have to wait for FDA to finish its substantive evaluation and issue a “no questions” letter before marketing the substance on the basis of its GRAS conclusion. [1]
That distinction is important because FDA’s substantive review could take considerably longer. Once a notice is filed, FDA proposes a 180-day response period, with the possibility of up to two additional 90-day extensions. [1]
Even without a premarket-approval requirement, brands may have business reasons to consider FDA review status when assessing launch risk.
Therefore, regulatory planning should occur early enough for teams to understand the applicable pathway, documentation strength, filing status, and potential commercial risk before making major launch commitments.
Stronger regulatory documentation does more than reduce compliance risk. It can also improve decision-making across R&D, quality, procurement, and commercialization.
Brands with organized ingredient regulatory files can evaluate supplier changes faster, identify documentation gaps earlier, and make more informed formulation decisions.
In addition, ingredient suppliers with well-supported regulatory positions may become more attractive partners if mandatory GRAS notification becomes final. Clear documentation can reduce uncertainty for downstream brands and manufacturers.
For brands, the strategic goal should not be to select ingredients merely because they have a GRAS Notice number. Instead, teams should select ingredients whose regulatory support aligns with the actual substance and intended use.
If FDA finalizes mandatory GRAS notification, regulatory review could become a more important upstream component of product development. Brands should integrate regulatory status with ingredient selection, supplier qualification, formulation change control, and commercialization planning rather than waiting until a product approaches launch.
FDA has proposed a significant change, but the rule is not final. The public comment period remains open through December 9, 2026. [1]
Therefore, brands do not need to make premature formulation changes based solely on the proposal. However, they can use this period to strengthen regulatory documentation, identify potential exposure, and establish processes that support better product development regardless of the final outcome.
Start by identifying the regulatory basis for substances used across the product portfolio.
For each ingredient or other relevant substance, document whether the intended use relies on GRAS status, dietary ingredient status, an applicable NDI pathway, an approved food additive regulation, or another regulatory basis.
For uses relying on GRAS, capture:
This inventory can quickly reveal where the company has strong documentation and where additional supplier follow-up may be appropriate.
Next, determine where products or ingredient suppliers rely on GRAS conclusions that were never voluntarily submitted to FDA.
These uses deserve particular attention because the proposed rule specifically seeks greater FDA visibility into independently concluded GRAS uses.
Brands do not necessarily need to create their own GRAS dossier for every supplier ingredient. Instead, they should determine who owns the underlying safety conclusion and whether appropriate documentation exists.
If the final rule resembles the proposal, this information could help determine whether an existing use qualifies for the streamlined transitional pathway or requires another action.
Brands can also strengthen supplier qualification now.
Rather than asking only, “Is this ingredient GRAS?” consider requesting documentation that answers:
For dietary supplement applications, brands should separately confirm the applicable dietary ingredient and NDI considerations rather than assuming GRAS documentation answers those questions.
Documentation only provides value when it applies to the product being developed.
For substances relying on GRAS status, compare the underlying regulatory support with the actual formulation. Look at the ingredient identity, supplier specifications, manufacturing process, serving or use level, product category, technical purpose, and other relevant conditions.
If those factors differ materially from the conditions evaluated in an existing GRAS conclusion, additional regulatory analysis may be appropriate.
This step is particularly valuable during reformulation, supplier changes, dose optimization, and expansion into new product categories.
Brands should consider adding a regulatory-status checkpoint to ingredient and formulation change control.
For example, changing an ingredient supplier should trigger more than a price and specification comparison. Teams should determine whether the new material has the same regulatory support as the previous material.
Similarly, changes in manufacturing method, specifications, purity, use level, or intended application should trigger appropriate regulatory review.
A simple checkpoint can prevent technical changes from unintentionally creating regulatory gaps.
GRAS readiness should not sit exclusively with one department.
R&D understands the formulation. Procurement manages supplier relationships. Quality controls specifications and change management. Regulatory evaluates the legal framework. Commercial teams manage launch expectations.
Therefore, brands should establish clear responsibility for collecting regulatory documentation and escalating potential gaps.
A defined workflow can be especially valuable for companies developing products quickly or managing large ingredient portfolios.
FDA is actively requesting public input, and the comment period runs through December 9, 2026. [1]
Companies should review whether specific provisions could materially affect their operations, ingredient portfolio, regulatory burden, or product-development process.
FDA is also requesting feedback on aspects of the proposed framework and its information-collection burden. Companies with relevant data or operational experience may want to participate individually or through an industry association.
Comments are submitted under Docket No. FDA-2025-N-3262. [1]
Finally, brands should distinguish readiness from overreaction.
FDA could modify the proposal after reviewing public comments. Definitions, exceptions, timelines, procedures, and other requirements may change before a final rule appears.
Therefore, brands generally should not reformulate products or abandon ingredients simply because an ingredient relies on an independent GRAS conclusion.
Instead, use the current period to improve visibility.
Know which regulatory pathway supports each relevant substance. Know where documentation lives. Know what suppliers are relying upon. And know which ingredients may require closer review if FDA finalizes mandatory GRAS notification.
Those actions can improve regulatory resilience without forcing unnecessary changes before FDA completes the rulemaking process.
The most useful action brands can take today is not wholesale reformulation. It is better regulatory visibility. By auditing ingredient status, strengthening supplier documentation, reviewing conditions of use, and integrating regulatory checkpoints into product development, brands can prepare for the proposed GRAS changes while making better formulation and sourcing decisions now.
FDA’s proposal does not require supplement brands to overhaul their portfolios today. However, it creates a useful reason to examine how regulatory information moves from ingredient suppliers through formulation, quality, regulatory review, and commercialization.
Importantly, mandatory notification should not be confused with mandatory FDA premarket approval. Under the proposed framework, a covered GRAS use would generally need to meet the notification requirement, but FDA is not proposing to convert GRAS into the traditional food additive approval process. [1]
Brands can use the following checklist to identify documentation gaps and prepare for potential changes.
Ingredient suppliers play an important role in regulatory readiness. However, a supplier statement such as “GRAS” or “self-GRAS” does not provide enough information by itself to evaluate a substance for a specific formulation.
Brands should ask questions that connect the ingredient’s regulatory support to the actual material being purchased and its intended conditions of use.
Start with the fundamental question:
What regulatory basis supports this substance for our intended application?
Ask the supplier to clarify whether it relies on:
This question helps prevent one of the most common sources of confusion: treating “GRAS” as a generic synonym for “legal ingredient.”
If the supplier relies on GRAS status, ask whether a GRAS notice has been submitted to FDA.
If so, request:
FDA maintains a public inventory of GRAS notices, which allows companies to review submitted notices and agency responses. [2]
However, an FDA “no questions” letter is not the same as FDA approval of an ingredient. FDA’s response reflects its evaluation of the notifier’s GRAS conclusion based on the information presented in that notice. [2]
Next, connect the regulatory file to the commercial ingredient.
Ask:
Is the ingredient you supply manufactured to the specifications and through the manufacturing process addressed by the cited GRAS documentation?
This question can become particularly important when suppliers offer multiple grades, sources, extraction methods, fermentation processes, carriers, concentrations, or other variations.
A shared ingredient name does not necessarily establish that every commercial version is covered by the same GRAS conclusion.
Brands should also tell suppliers how they intend to use the substance.
Ask whether the supporting documentation covers:
If the intended application falls outside the evaluated conditions, regulatory review may be necessary.
This is one reason regulatory conversations should happen during formulation development rather than immediately before launch.
GRAS documentation may have been prepared years earlier. Therefore, brands should ask whether anything relevant has changed.
Potential changes include:
FDA’s proposal specifically addresses circumstances in which differences from a previously evaluated substance or use may affect reliance on existing regulatory support. [1]
Brands should know whether the regulatory position belongs to the ingredient manufacturer, distributor, another supplier, or another organization.
Ask:
Who maintains the GRAS dossier and supporting safety evidence?
Then ask who will be responsible for maintaining regulatory support if FDA finalizes mandatory notification.
This can become particularly important when brands purchase through distributors rather than directly from the ingredient manufacturer.
An independent GRAS conclusion is not inherently synonymous with inadequate scientific support. Under the current framework, GRAS status still requires an appropriate basis for safety and general recognition under the intended conditions of use. [2]
However, brands should understand what sits behind the supplier’s conclusion.
Questions may include:
The objective is not necessarily to obtain every confidential component of a supplier’s dossier. Instead, brands need sufficient regulatory assurance to qualify the ingredient appropriately.
This may become one of the most useful supplier questions during the rulemaking period.
For ingredients relying on independent GRAS conclusions, ask suppliers:
Have you evaluated whether this use would fall within the proposed mandatory notification framework, and how would you respond if the rule becomes final?
A supplier may not yet have a definitive answer — and FDA could substantially modify the proposal. However, asking the question helps brands identify which suppliers are actively monitoring the regulatory environment.
The proposed GRAS rule highlights a broader principle for supplement brands: regulatory documentation should be part of ingredient quality, not separate from it. Purity, potency, sensory performance, stability, supply continuity, and price all influence ingredient selection. Regulatory support belongs in that same evaluation.
For manufacturers and brands working together on new formulations, early regulatory conversations can also prevent wasted development effort. Identifying an unsupported use before pilot production is considerably easier than resolving it shortly before commercialization.
Don’t ask suppliers only whether an ingredient is “GRAS.” Ask what regulatory basis supports the specific material, who owns that support, what conditions it covers, whether the commercial ingredient matches the documented substance, and how the supplier plans to respond if mandatory GRAS notification becomes final.
FDA’s proposed mandatory GRAS notification framework creates potential compliance work, but it also creates an opportunity for supplement brands to strengthen how they approach ingredients, suppliers, and product development.
The companies best positioned for regulatory change will not necessarily be those with the largest regulatory departments. Instead, they will be brands that can quickly understand what is in their products, why each substance can lawfully be used, what documentation supports that position, and whether their suppliers can support it.
Regulatory evaluation works best when it begins alongside formulation — not after a formula is complete.
When brands evaluate regulatory status during ingredient selection, teams can identify potential concerns before investing heavily in samples, sensory optimization, packaging, claims, or commercialization.
This approach is particularly important for innovative ingredients and products that may cross regulatory categories. A substance appropriate for one intended use does not automatically carry the same regulatory position into another.
Therefore, R&D, regulatory, quality, procurement, and manufacturing teams should share information early. That coordination can help brands make faster, better-supported decisions.
The proposed rule also provides an opportunity to rethink what constitutes a well-qualified ingredient supplier.
Price, lead time, specifications, testing, and supply reliability remain important. However, regulatory transparency deserves similar attention.
A strong supplier should be able to explain the regulatory basis supporting its ingredient and provide appropriate documentation. When GRAS status applies, brands should understand the substance identity, applicable conditions of use, relevant FDA notification history, and whether the commercial material aligns with the supporting documentation.
As regulatory expectations evolve, suppliers that maintain clear and current documentation may reduce uncertainty for brands and manufacturers.
An ingredient regulatory-status audit can also uncover concentration risk.
For example, a brand may discover that several important formulations depend on one supplier’s independent GRAS conclusion. Another ingredient may have strong documentation but only for conditions that differ from the brand’s intended use.
Finding those issues now provides time to ask questions, assess alternatives, and improve documentation without the pressure of an immediate regulatory deadline.
The goal should not be to eliminate every ingredient associated with an independent GRAS conclusion. Instead, brands should understand where potential regulatory dependencies exist and make informed decisions based on actual risk.
Regulatory readiness can also support speed.
A product that reaches final development with unresolved ingredient questions may require additional supplier outreach, regulatory analysis, or formulation changes. In contrast, teams that evaluate regulatory status alongside technical feasibility can resolve many questions earlier.
That can become increasingly valuable as supplement brands pursue differentiated ingredients and faster innovation cycles.
Importantly, FDA’s proposal creates a mandatory notification framework, not a conventional premarket approval system. For covered GRAS uses, the proposal would increase FDA visibility without simply converting GRAS into the food additive petition process. [1]
Nevertheless, stronger documentation and earlier regulatory planning can help companies make more informed decisions about commercialization risk.
The proposal remains exactly that — a proposal.
FDA may revise provisions after reviewing public comments, and the final rule could differ from the August 2026 version. Therefore, brands should avoid unnecessary reformulation or sourcing changes based solely on assumptions about what the final requirements will contain.
Instead, this is an appropriate time to improve visibility.
Audit regulatory status. Organize documentation. Talk with suppliers. Strengthen change control. Identify potential gaps. Monitor the rulemaking.
Those actions provide value even if FDA ultimately changes significant portions of the proposal.
For supplement brands, regulatory readiness works best when it connects directly with formulation, sourcing, quality, manufacturing, stability, sensory performance, and commercialization.
That is where an experienced manufacturing partner can add value.
At Intermountain Nutrition, we work with supplement brands to develop custom formulations with manufacturability, quality, scalability, and commercialization in mind. As regulatory expectations evolve, involving knowledgeable formulation and manufacturing teams early can help brands ask better questions, identify potential challenges sooner, and build products on a stronger foundation.
The proposed GRAS rule is another reminder that successful supplement development requires more than selecting compelling ingredients. Brands also need to understand how those ingredients fit within the larger regulatory, technical, and commercial picture.
Don’t wait for a final GRAS rule to build better regulatory visibility. Brands that connect ingredient documentation, supplier qualification, formulation, quality, and regulatory strategy can reduce uncertainty while creating a more resilient product-development process.
No. As of August 2026, FDA’s mandatory GRAS notification requirements remain a proposed rule. FDA published the proposal in the Federal Register on August 11, 2026, and comments are currently due by December 9, 2026.
That distinction is important because the requirements, exceptions, procedures, and implementation timelines could change before FDA publishes a final rule. Companies should therefore avoid presenting the proposal as current law.
However, brands do not need to wait to improve regulatory readiness. Ingredient-status audits, supplier-documentation reviews, change-control improvements, and clearer internal ownership can strengthen product development regardless of the final outcome.
For companies that believe specific provisions could affect their operations, FDA is accepting comments under Docket No. FDA-2025-N-3262.
FDA is proposing to substantially change companies’ ability to rely on an unnotified independent GRAS conclusion for covered uses. Under the current framework, a company may independently conclude that an intended use is GRAS without voluntarily submitting that conclusion to FDA.
If the rule is finalized substantially as proposed, covered uses generally would become subject to mandatory FDA notification unless an applicable exception applies.
However, describing the proposal simply as “eliminating GRAS” would be inaccurate. The GRAS standard and pathway would remain. The major change is that FDA would gain substantially greater visibility into uses relying on GRAS conclusions.
Additionally, FDA proposes a streamlined, time-limited mechanism for certain qualifying existing uses that entered interstate commerce before the final rule’s effective date.
Not uniformly. This is one of the most important distinctions for supplement companies to understand.
FDA explains in the proposed rule that an ingredient described in section 201(ff) of the FD&C Act when in, or intended for use in, a dietary supplement is excluded from the statutory food-additive definition. Consequently, that dietary ingredient is not classified as GRAS through the GRAS exclusion within that definition.
Dietary ingredients can instead involve other dietary supplement requirements, including New Dietary Ingredient provisions when applicable.
Therefore, brands should not assume that every dietary ingredient in every dietary supplement will require a GRAS notice. Instead, determine the regulatory basis for the specific substance under its specific intended conditions of use.
No. FDA’s proposal includes exceptions and transition provisions, so brands should not assume every substance associated with GRAS will require an entirely new full GRAS notice.
For example, FDA proposes an exception where an applicable FDA “no questions” letter already covers the same substance under the same conditions of intended use. FDA also proposes a streamlined pathway for certain existing independently concluded GRAS uses introduced into interstate commerce before a final rule’s effective date.
The details matter, however. Differences involving substance identity, manufacturing, specifications, food categories, use levels, technical effect, or other conditions could affect whether existing regulatory support applies.
Therefore, the better question is not simply whether an ingredient “has GRAS.” Brands should determine whether existing support covers their actual material and intended use.
FDA proposes a temporary streamlined submission pathway for certain qualifying substances and uses already introduced into interstate commerce under the GRAS provision before the final rule’s effective date.
Under the proposal, companies would submit specified information about the substance and existing conditions of use. The streamlined submission period would remain available for one year after the final rule’s effective date.
However, inclusion on FDA’s resulting public list would not mean FDA had affirmatively reviewed and determined the substance to be GRAS. FDA could subsequently determine that additional regulatory review, a complete GRAS notice, or another applicable pathway is necessary.
For that reason, companies relying on independent GRAS conclusions should begin identifying supporting documentation and commercial-history records rather than waiting for a final rule.
The proposal should not be characterized as converting GRAS into a traditional FDA premarket approval program.
For covered uses, FDA proposes mandatory notification. The notification requirement would be satisfied when FDA files a complete GRAS notice, rather than requiring the notifier to wait until FDA completes its substantive review and issues a “no questions” response.
FDA’s subsequent review could still have important regulatory and commercial implications. Therefore, brands may choose to consider FDA review status when evaluating launch risk.
The distinction is important: mandatory notification increases FDA visibility and oversight, but notification is not the same regulatory mechanism as obtaining approval of a food additive petition.
Under the proposed framework, FDA generally would have 180 days after filing to respond to a GRAS notice. The proposal also provides for up to two additional 90-day extensions under specified circumstances. Therefore, substantive FDA evaluation could potentially extend to approximately 360 days.
However, that timeline should not be interpreted as a mandatory waiting period before commercialization in every case. Under the proposal, filing of a complete notice would satisfy the notification requirement.
Still, the potential review timeline reinforces the value of early regulatory planning. Companies developing products that depend on novel GRAS uses should consider regulatory strategy alongside formulation, sourcing, manufacturing, and launch planning rather than treating it as a final-stage compliance exercise.
Start with visibility rather than reformulation.
Brands should identify the regulatory basis supporting relevant substances, determine where GRAS status is relied upon, locate applicable GRAS notices and FDA response letters, and identify independently concluded GRAS uses. They should also confirm whether supporting documentation aligns with current ingredient specifications and intended conditions of use.
Next, strengthen supplier qualification. Ask suppliers what regulatory basis supports their materials, what conditions their documentation covers, and whether manufacturing or specification changes have occurred.
Finally, monitor FDA’s rulemaking and reassess when material developments occur. Because the rule remains proposed, companies should avoid unnecessary changes based on requirements that may still evolve.
The objective today is regulatory readiness — not regulatory overreaction.
[1] U.S. Food and Drug Administration. (2026). Substances Generally Recognized as Safe; Proposed Rule. Federal Register, 91 FR 51834. Published August 11, 2026.
Primary regulatory source for the proposed mandatory GRAS notification framework, exceptions, transition provisions, streamlined submissions, FDA review procedures, dietary supplement considerations, implementation timelines, and public comment period.
[2] U.S. Food and Drug Administration. (2026). Generally Recognized as Safe (GRAS).
FDA’s primary GRAS resource center explains the statutory and regulatory framework for GRAS substances and provides access to the proposed rule, notification program, GRAS Notice Inventory, guidance documents, and related resources.
[3] U.S. Food and Drug Administration. (2026). Substances Generally Recognized as Safe (Proposed Rule): Economic Impact Analysis.
FDA’s economic analysis explains the expected benefits, costs, administrative burden, and operational effects of mandatory GRAS notification. FDA estimates the proposal’s annualized costs at approximately $10.5 million at a 3% discount rate over 10 years, with a range of $4.1 million to $24.6 million.
[4] U.S. Department of Health and Human Services. (2026). HHS Announces Proposed GRAS Rule.
HHS overview of the proposed rule and the administration’s rationale for moving from voluntary to mandatory GRAS notification.
[5] U.S. Food and Drug Administration. (2016; current FDA guidance). Frequently Asked Questions About GRAS for Substances Intended for Use in Human or Animal Food: Guidance for Industry.
FDA guidance addressing common questions about GRAS status, the regulatory process, scientific evidence, and conditions of intended use.
[6] U.S. Food and Drug Administration. Understanding How FDA Regulates Food Additives and GRAS Ingredients.
FDA explains the distinction between food additives and GRAS uses, including the requirement that GRAS safety be generally recognized among qualified experts and supported by publicly available information.
[7] U.S. Food and Drug Administration. Determining the Regulatory Status of a Food Ingredient.
FDA explains how ingredient identity, specifications, purity, and conditions of use affect regulatory status. This source is particularly relevant to supplier qualification, formulation changes, and determining whether regulatory support applies to a specific commercial ingredient.
[8] U.S. Food and Drug Administration. (2016). FDA Issues Final Rule on Food Ingredients That May Be “Generally Recognized as Safe.”
Historical FDA source explaining the 2016 GRAS final rule, the scientific standard for GRAS conclusions, and the voluntary notification procedure that the 2026 proposal seeks to change.
[9] Latham & Watkins LLP. (2026). FDA Proposes to Mandate GRAS Notices for Food Substances.
Legal analysis of the proposed rule, including implications for companies relying on independent GRAS conclusions and considerations surrounding mandatory notification.
[10] Holland & Knight LLP. (2026). From Voluntary to Mandatory: FDA’s Proposed GRAS Rule.
Legal and regulatory analysis of FDA’s proposal and its potential implications for food and ingredient companies.
[11] Nutritional Outlook. (2026). FDA Proposes Mandatory GRAS Notification.
Supplement and nutrition industry coverage of FDA’s proposed GRAS changes and their relevance to companies operating in the ingredient and nutrition markets.
[12] U.S. Food and Drug Administration. Post-Market Determinations That the Use of a Substance Is Not GRAS.
FDA’s resource documenting circumstances in which the agency has determined that an intended use does not satisfy GRAS criteria. It illustrates why companies should not treat “GRAS” as a universal or permanent designation independent of the substance and its intended conditions of use.
https://intermountainnutrition.com/wp-content/uploads/2026/09/andrographis.jpg 1200 1200 Larisa Graham https://intermountainnutrition.com/wp-content/uploads/2026/01/IMN-gradient-logo-NEW.png Larisa Graham2026-09-14 09:00:002026-09-14 12:53:59Andrographis for Immune Support https://intermountainnutrition.com/wp-content/uploads/2026/09/stock-formula-elderberry-gummy-07.jpg 1200 1200 Larisa Graham https://intermountainnutrition.com/wp-content/uploads/2026/01/IMN-gradient-logo-NEW.png Larisa Graham2026-09-13 05:27:342026-09-13 06:53:38STOCK FORMULA: Elderberry Gummies for Immune Support https://intermountainnutrition.com/wp-content/uploads/2026/09/propolis-for-immunity-support-17.jpg 1200 1200 Larisa Graham https://intermountainnutrition.com/wp-content/uploads/2026/01/IMN-gradient-logo-NEW.png Larisa Graham2026-09-11 09:00:002026-09-08 04:53:15Inside the Hive: How Propolis Supports Seasonal Wellness
Akkermansia Muciniphila in Supplement Formulation